<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04561570</url>
  </required_header>
  <id_info>
    <org_study_id>The REVIVE Study</org_study_id>
    <nct_id>NCT04561570</nct_id>
  </id_info>
  <brief_title>Long Term Outcomes of Vivity Intra Ocular Lens(IOL) Versus Control</brief_title>
  <acronym>REVIVE</acronym>
  <official_title>Long Term Outcomes of Vivity IOL Versus Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Berdahl, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cathleen McCabe, MD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvey Reiser, MD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>T. Hunter Newsom, MD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vance Thompson Vision</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the long-term (&gt;1 yr) outcomes of the Vivity IOL. The investigator will use similar&#xD;
      measurements and procedures to the ones performed on these subjects during the FDA clinical&#xD;
      trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 17, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Best Corrected Distance Visual Acuity (BCDVAA)</measure>
    <time_frame>After 1 year post-op</time_frame>
    <description>Best correct distance visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Best Corrected Intermediate Visual Acuity (BCIVA)</measure>
    <time_frame>After 1 year post-op</time_frame>
    <description>Best correct intermediate visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Defocus Curve</measure>
    <time_frame>After 1 year post-op</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uncorrected Distance Visual Acuity (UCDVA)</measure>
    <time_frame>After 1 year post-op</time_frame>
    <description>Uncorrected Distance Visual Acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UCNVA</measure>
    <time_frame>After 1 year post-op</time_frame>
    <description>Uncorrected Near Visual Acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyphotopsia rate</measure>
    <time_frame>After 1 year post-op</time_frame>
    <description>Demonstrated by responses on questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative IOLSAT</measure>
    <time_frame>After 1 year post-op</time_frame>
    <description>Questionnaire about satisfaction with your vision after surgery. 0-4 scale with 4 being the worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Post-operative QUVID)</measure>
    <time_frame>After 1 year post-op</time_frame>
    <description>Questionnaire about the quality of your vision after surgery.0-4 scale with 4 being the worse outcome</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Study Group: Vivity ACRYSOF IQ IOL</arm_group_label>
    <description>Subjects that were implanted with the Vivity ACRYSOF IQ extended depth of focus IntaOcular Lens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group: ACRYSOF IQ IOL</arm_group_label>
    <description>Control Group: Subject that were implanted with the ACRYSOF IQ Monofocal IntaOcular Lens</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Study Group</intervention_name>
    <description>Subjects that were implanted with the Vivity ACRYSOF IQ extended depth of focus IntaOcular Lens</description>
    <arm_group_label>Study Group: Vivity ACRYSOF IQ IOL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control Group</intervention_name>
    <description>Subject that were implanted with the ACRYSOF IQ Monofocal IntaOcular Lens</description>
    <arm_group_label>Control Group: ACRYSOF IQ IOL</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        45-60 subjects will be enrolled (30-45 subjects that received the Vivity IOL and 15-20&#xD;
        subjects that received the control lens in the FDA clinical trial) across up to five&#xD;
        investigational sites.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Must have participated in the FDA study at one of the included sites&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vance Thompson Vision</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 11, 2020</study_first_submitted>
  <study_first_submitted_qc>September 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Vance Thompson Vision</investigator_affiliation>
    <investigator_full_name>John Berdahl, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

